A bioassay of technical-grade @entity69649 for possible carcinogenicity was conducted using Fischer 344 @entity35 and B6C3F1 @entity19 . @entity69649 was administered in the feed, at either of two concentrations, to groups of 50 male and 47 to 50 females animals of each species. The time-weighted average dietary concentrations used in the @entity35 bioassay were 0.008, 0.03, 0.004, and 0.01 percent for low dose males, high dose males, low dose females, and high dose females, respectively. The time-weighted average dietary concentrations used in the @entity19 bioassay were 0.008, 0.04, 0.004, and 0.04 percent for low dose males, high dose males, low dose females, and high dose females, respectively. After a 78-week period of compound administration, observation of the @entity35 continued for an additional 28 to 30 weeks and observation of the @entity19 continued for an additional 17 or 18 weeks. For each species, 47 to 50 animals of each sex were placed on test as controls. In both, species, adequate numbers of animals in all groups survived sufficiently long to be at risk from late-appearing @entity5 . The incidence of @entity157 was significantly increased in dosed male @entity35 and the incidence of neoplastic nodules of the liver was significantly increased in dosed female @entity35 . A significant increase in the combined incidence of @entity957 or @entity1185 of the Zymbal's gland, the ear canal, or the skin of the ear was observed among high dose male @entity35 . A significant increase in mammary @entity420 was observed among dosed female @entity35 . The incidence of @entity157 was significantly increased among female @entity19 , but no significant @entity96 was observed among male @entity19 . Under the conditions of this bioassay, @entity69649 was carcinogenic to Fischer 344 @entity35 of both sexes, causing increased incidences of @entity157 and @entity1544 in male @entity35 , neoplastic nodules of the liver in female @entity35 , and mammary @entity420 in female @entity35 . @entity69649 was also carcinogenic to female B6C3F1 @entity19 , causing an increased incidence of @entity157 . The compound was not carcinogenic to male B6C3F1 @entity19 .

Bioassay of XXXX for possible carcinogenicity.

@entity96 :: ('MESH:D008113', 'Disease') :: ['increase in liver tumors'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity69649 :: ('MESH:C032041', 'Chemical') :: ['Hydrazobenzene', 'hydrazobenzene'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous-cell carcinomas'] @entity1185 :: ('MESH:D010212', 'Disease') :: ['squamous-cell papillomas'] @entity1544 :: ('MESH:D018307', 'Disease') :: ["Zymbal's gland squamous-cell neoplasms"] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma', 'hepatocellular carcinomas'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']
@entity69649 :: (MESH:C032041,Chemical) :: ['hydrazobenzene']
